Efficacy and safety of nucleoside antiviral drugs for treatment of recurrent herpes labialis: a systematic review and meta‐analysis
Authors:
- 25 January 2017
- journal article
- review article
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 46 (8) , 561-568
Abstract
Objectives: To evaluate the effectiveness and safety of nucleoside antiviral drugs for the treatment of recurrent herpes labialis.Methods: Randomized controlled trials that examined the effectiveness and/or safety of nucleoside antiviral drugs for recurrent herpes labialis were identified via a literature search. The parameters used to measure efficacy were time to healing of classic and all lesions, time to resolution of pain, and percentage of aborted lesions. Safety was assessed by evaluating the adverse events reported during treatment. Subgroup analyses based on the mode of application (topical/systemic) and type of nucleoside antiviral drugs were performed, as were sensitivity analyses of studies with a low risk of bias.Results: Our analysis included 16 publications reporting 25 randomized controlled trials (8453 patients). Nucleoside antiviral drugs decreased the time to healing of all lesions (mean difference: −0.74 days; 95% confidence interval: −0.86, −0.62), especially classic lesions (mean difference: −1.09 days; 95% confidence interval: −1.27, −0.92). They also reduced the time to resolution of pain (mean difference: −0.38 days; 95% confidence interval: −0.58, −0.18) and increased the percentage of aborted lesions (rate ratio: 1.15; 95% confidence interval: 1.07, 1.23). Valaciclovir more effectively reduced the time to healing of all lesions and the time to resolution of pain than did aciclovir. Both nucleoside antiviral drugs increased the percentage of aborted lesions, whereas penciclovir and famciclovir did not.Conclusions: Nucleoside antiviral drugs are safe and beneficial for the treatment of recurrent herpes labialis; both systemic and topical formulations are recommended. Valaciclovir is more effective than aciclovir, especially in reducing the time to healing of lesions.Keywords
Funding Information
- National Natural Science Foundation of China (81270040, 81670998, 81321002)
This publication has 22 references indexed in Scilit:
- Recent developments in anti-herpesvirus drugsBritish Medical Bulletin, 2013
- Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: A randomized, double-blind, placebo-controlled, patient-initiated clinical trialJournal of the American Academy of Dermatology, 2011
- Single-dose, patient-initiated famciclovir: A randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialisJournal of the American Academy of Dermatology, 2006
- High-Dose, Short-Duration, Early Valacyclovir Therapy for Episodic Treatment of Cold Sores: Results of Two Randomized, Placebo-Controlled, Multicenter StudiesAntimicrobial Agents and Chemotherapy, 2003
- Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: A randomized, double-blind, placebo-controlled trialClinical Therapeutics, 2000
- Treatment of Recurrent Herpes Simplex Labialis with Oral AcyclovirThe Journal of Infectious Diseases, 1990
- Iontophoresis of Vidarabine Monophosphate for Herpes OrolabialisThe Journal of Infectious Diseases, 1986
- Topical acyclovir in the management of recurrent herpes labialisBritish Journal of Dermatology, 1983
- Successful treatment of herpes labialis with topical acyclovir.BMJ, 1983
- Acyclovir — A review of the preclinical and early clinical data of a new antiherpes drugAntiviral Research, 1981